MBRX logo

Moleculin Biotech (MBRX) Company Overview

Profile

Full Name:

Moleculin Biotech, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 2, 2016

Indexes:

Not included

Description:

Moleculin Biotech (MBRX) is a biotechnology company focused on developing innovative treatments for cancer and viral infections. They create new drugs that target specific diseases, aiming to improve patient outcomes and advance medical science. Their research includes both clinical and preclinical studies to bring new therapies to market.

Events Calendar

Earnings

Next earnings date:

Mar 21, 2025

Recent quarterly earnings:

Nov 8, 2024

Recent annual earnings:

Mar 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 22, 2024

Analyst ratings

Recent major analysts updates

Mar 3, 25 HC Wainwright & Co.
Buy
Nov 12, 24 Maxim Group
Buy
Apr 12, 24 Roth MKM
Buy
Mar 26, 24 Maxim Group
Buy
Dec 14, 23 HC Wainwright & Co.
Buy
Apr 18, 23 Roth MKM
Buy
Mar 24, 23 Oppenheimer
Outperform
Oct 17, 19 Oppenheimer
Outperform
Nov 14, 18 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Moleculin Biotech?
  • Does Moleculin Biotech pay dividends?
  • What sector is Moleculin Biotech in?
  • What industry is Moleculin Biotech in?
  • What country is Moleculin Biotech based in?
  • When did Moleculin Biotech go public?
  • Is Moleculin Biotech in the S&P 500?
  • Is Moleculin Biotech in the NASDAQ 100?
  • Is Moleculin Biotech in the Dow Jones?
  • When was Moleculin Biotech's last earnings report?
  • When does Moleculin Biotech report earnings?
  • Should I buy Moleculin Biotech stock now?

What is the ticker symbol for Moleculin Biotech?

The ticker symbol for Moleculin Biotech is NASDAQ:MBRX

Does Moleculin Biotech pay dividends?

No, Moleculin Biotech does not pay dividends

What sector is Moleculin Biotech in?

Moleculin Biotech is in the Healthcare sector

What industry is Moleculin Biotech in?

Moleculin Biotech is in the Biotechnology industry

What country is Moleculin Biotech based in?

Moleculin Biotech is headquartered in United States

When did Moleculin Biotech go public?

Moleculin Biotech's initial public offering (IPO) was on June 2, 2016

Is Moleculin Biotech in the S&P 500?

No, Moleculin Biotech is not included in the S&P 500 index

Is Moleculin Biotech in the NASDAQ 100?

No, Moleculin Biotech is not included in the NASDAQ 100 index

Is Moleculin Biotech in the Dow Jones?

No, Moleculin Biotech is not included in the Dow Jones index

When was Moleculin Biotech's last earnings report?

Moleculin Biotech's most recent earnings report was on Nov 8, 2024

When does Moleculin Biotech report earnings?

The next expected earnings date for Moleculin Biotech is Mar 21, 2025

Should I buy Moleculin Biotech stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions